Rezafungin: First Approval.

Abstract

Rezafungin (Rezzayo™), an intravenous once-weekly echinocandin that inhibits 1,3-β-D-glucan synthase, is being developed by Cidara Therapeutics. In March 2023, rezafungin received approval in the USA for the treatment of candidaemia and invasive candidiasis in patients aged ≥ 18 years who have limited or no alternative treatment options. Rezafungin is also being developed for the prevention of invasive fungal diseases in blood and marrow transplant recipients. This article summarizes the milestones in the development of rezafungin leading to the first approval for the treatment of candidaemia and invasive candidiasis.

• Authors: Yahiya Y Syed
• Journal: Drugs (Drugs) Vol. 83 Issue 9 Pg. 833-840 (Jun 2023) ISSN: 1179-1950 [Electronic] New Zealand
• PMID: 37212966 (Publication Type: Journal Article, Review)
• Copyright: © 2023. The Author(s), under exclusive licence to Springer Nature Switzerland AG.

Chemical References

• Rezafungin
• Antifungal Agents
• Echinocandins

Topics

• Humans
• Antifungal Agents (pharmacology, therapeutic use)
• Echinocandins (pharmacology, therapeutic use)
• Candidiasis, Invasive (drug therapy)